9 commercial payer policies list P07.39. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
9 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of P07.39 |
|---|---|---|
| Nitric Oxide, Inhalational (INO) | Jul 18, 2023 | Covered |
| Palivizumab (Synagis) | Feb 15, 2024 | Covered |
| Quantitative EEG (Brain Mapping) | Apr 25, 2023 | Covered |
| Salivary Tests | Aug 31, 2023 | Covered |
| T-Wave Alternans | Jul 28, 2023 | Covered |
| Policy | Effective | Status of P07.39 |
|---|---|---|
| Inhaled Nitric Oxide | Jul 1, 2026 | Covered |
| Outpatient Laboratory-based Blood Glucose Testing | Jul 1, 2026 | Covered |
| Thyroid Testing | Apr 15, 2026 | Covered |
| Policy | Effective | Status of P07.39 |
|---|---|---|
| Extended Ophthalmoscopy | Not recorded | Covered |